Anti Aging S is a prescription therapy used for healthy aging support.

Patients seeking support for healthy aging support may qualify after evaluation by a licensed provider.

Yes. Anti-Aging S is a compounded prescription topical medication containing tretinoin and estriol, both of which require a valid prescription from a licensed healthcare provider. A telehealth consultation and medical intake are required before dispensing to confirm suitability, ensure appropriate patient counseling, and establish the correct application protocol.

The most common side effects are tretinoin-related during the initial 2 to 4 week adjustment period: mild to moderate redness, peeling, dryness, or flaking as epidermal cell turnover accelerates. Increased UV sensitivity is expected throughout therapy. Estriol may cause mild local skin sensitivity in highly reactive patients. Alpha lipoic acid may produce a transient sulfurous odor on application. Seek provider evaluation for persistent severe irritation, signs of allergic contact dermatitis, or any unexpected systemic symptoms.

Anti-Aging S is contraindicated during pregnancy — tretinoin is teratogenic and use must be discontinued immediately if pregnancy occurs or is planned. It is not appropriate during breastfeeding. Patients with known retinoid sensitivity or allergy, active eczema, active rosacea, or severely compromised facial skin should not use this product. Patients with a personal history of estrogen receptor-positive breast cancer, endometrial cancer, or other hormone-sensitive malignancies must discuss use with their oncologist before initiating.

Other topical retinoids (adapalene, tazarotene, retinol) must not be used concurrently — combining multiple retinoids dramatically increases irritation without proportional benefit. Topical exfoliating acids (AHAs and BHAs) should be avoided during the initial adjustment period. Benzoyl peroxide inactivates tretinoin on direct contact and must not be applied on the same evening. Photosensitizing medications (certain antibiotics, thiazide diuretics, amiodarone) may additively increase UV sensitivity during tretinoin therapy. Discuss all topical and systemic medications with your provider.

Patients with a history of hormone-sensitive malignancy require oncological discussion before using any topical estriol-containing preparation, even though systemic absorption from low-concentration facial application is generally minimal. Those with active inflammatory skin conditions should not begin therapy until skin is stable. Patients taking oral retinoids (isotretinoin) must not use topical tretinoin concurrently. Your provider will review your full history before prescribing.